🔴 Cerenome is trading 9.78% down in pre-market after reporting a $9.0 million second-quarter loss

Cerenome is trading at $3.32, down 9.78% in pre-market on August 17, 2026, after reporting a $9.0 million second-quarter loss and $1.31 loss per share.

• Earnings missed the consensus estimate of a $0.96 loss per share, while revenue reached only $411,000.
• The company reported a sharply wider operating loss, reflecting increased clinical and commercial spending.